HBeAg阴性慢性乙型肝炎获得HBsAg清除与血清白细胞介素17水平的关系

曹振环; 柳雅立; 马丽娜; 鲁俊锋; 金怡; 何智敏; 郑燕红; 陈新月

doi:10.3969/j.issn.1001-5256.2016.07.015

HBeAg阴性慢性乙型肝炎获得HBsAg清除与血清白细胞介素17水平的关系

DOI: 10.3969/j.issn.1001-5256.2016.07.015

首都医科大学附属北京佑安医院肝病综合科

基金项目:

国家“十二五”科技重大专项(013ZX1000 2002-006)；首都临床特色应用研究(Z151100004015181.Z161100000516018)；首都卫生发展科研专项项目(首发2011-2018-08,首发2016-1-2183)；北京佑安医院肝病艾滋病基金中青年孵育项目(YNKT20160021)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2103
- HTML全文浏览量: 12
- PDF下载量: 460
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-03
- 出版日期: 2016-07-20

Association between serum level of interleukin-17 and HBsAg clearance in patients with HBsAg-negative chronic hepatitis B

Department of Liver Disease,Beijing YouAn Hospital,Capital Medical University

Research funding:

摘要

摘要: 目的探讨聚乙二醇干扰素（PEG-IFN）治疗HBeAg阴性慢性乙型肝炎（CHB）发生HBsAg清除与血清白细胞介素（IL）17水平的关系。方法选择2012年1月-2015年1月于北京佑安医院就诊的HBeAg阴性CHB患者13例,经PEG-IFN治疗24周,其中6例获得HBsAg清除（R组）,7例未获得HBsAg清除（NR组）。用Luminex技术检测患者基线、治疗12周和24周血清IL-17水平。同时检测10例健康人和6例急性乙型肝炎（AHB）患者发病时的血清IL-17水平。计量资料两组间比较采用t检验,多组间比较采用方差分析,进一步两两比较采用SNK-q检验;计数资料组间比较采用χ2检验。结果 AHB组基线血清IL-17水平最高,其次是CHB组,健康对照组最低,3组间比较差异有统计学意义（P<0.05）。CHB患者经PEG-IFN治疗24周后,IL-17水平较基线明显下降（P=0.044）。R组基线血清IL-17水平高于NR组,而且在PEG-IFN治疗后明显下降;而NR组IL-17升高或降低不明显。结论 PEG-IFN治疗HBeAg阴性CHB患者,IL-1...
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 肝炎表面抗原,乙型 /
- 白细胞介素17
Abstract: Objective To investigate the association between HBsAg clearance and serum level of interleukin- 17( IL- 17) in HBeAg-negative chronic hepatitis B( CHB) patients treated by pegylated interferon( PEG- IFN). Methods A total of 13 HBeAg- negative CHB patients who visited Beijing You An Hospital from January 2012 to January 2015 were enrolled. After the 24- week treatment with PEG-IFN,6 achieved HBsAg clearance( R group) and 7 did not achieve HBsAg clearance( NR group). The Luminex technology was used to measure the serum level of IL- 17 at baseline and weeks 12 and 24 of treatment. Ten healthy controls and 6 patients with acute hepatitis B( AHB) were enrolled and serum level of IL- 17 was measured. An analysis of variance was used for comparison of continuous data between multiple groups,and the SNK- qtest was used for further pairwise comparison; the t- test was used for comparison of continuous data between any two groups; the chi- square test was used for comparison of categorical data between groups. Results The AHB group had the highest serum level of IL- 17 at baseline,followed by the CHB group and healthy control group,and the serum level of IL- 17 at baseline showed significant differences between the three groups( P < 0. 05). After the PEG- IFN treatment for 24 weeks,HBeAg- negative CHB patients showed a significant reduction in serum level of IL- 17( P = 0. 044). R group had a significantly higher serum level of IL- 17 than NR group and showed a significant reduction in the serum level of IL- 17 after PEG- IFN treatment,while NR group showed no significant increase or reduction in the serum level of IL- 17. Conclusion In the PEG- IFN treatment for HBeAg- negative CHB patients,a high serum level of IL- 17 at baseline and a significant reduction in serum level of IL- 17 helps with HBsAg clearance.
- hepatitis B /
- chronic /
- hepatitis B e antigens /
- hepatitis B surface antigens

HTML全文

参考文献(14)

[1]LIAW YF,CHU CM.Hepatitis B virus infection[J].Lancet,2009,373(9663):582-592.

[2]LIAW YF,LEUNG N,KAO JH,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update[J].Hepatol Int,2008,2(3):263-283.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines[J].J Hepatol,2009,50(2):227-242.

[4] FENG H,YIN J,HAN YP,et al.Sustained changes of treg and Th17cells during interferon-αtherapy in patients with chronic hepatitis B[J].Viral Immunol,2015,28(8):412-417.

[5] LIANG XS,LI CZ,ZHOU Y,et al.Changes of treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection[J].BMC Gastroenterology,2012,12:43-51.

[6]YANG B,ZHAO CY,WANG YD,et al.The changes of Th17 cells in the pathogenesis and aggravation of chronic hepatitis B[J].Chin J Infect Dis,2012,30(8):472-477.(in Chinese)杨波,赵彩彦,王亚东,等.Th17细胞在慢性乙型肝炎及其重症化中的变化[J].中华传染病杂志,2012,30(8):472-477.

[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[8]LIU JJ,LI QY,GUAN S,et al.Expression levels of IL-37 and HBeA g seroconversion in chronic HBV patients[J].Chin J Immunol,2015,31(11):1545-1548,1552.(in Chinese)刘晶晶,李庆彦,管珊,等.慢性乙型肝炎患者中IL-37的水平与HBeA g血清转换的关系研究[J].中国免疫学杂志,2015,31(11):1545-1548,1552.

[9] GOODBOURN S,DIDCOCK L,RANDALL RE.Interferons:cell signalling,immune modulation,antiviral response and virus counter measures[J].J Gen Virol,2000,81(10):2341-2364.

[10]RICO MA,QUIROGA JA,SUBIRD,et al.Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha[J].Hepatology,2001,33(1):295-300.

[11] SRENATHAN U,STEEL K,TAAMS LS.IL-17+CD8+T cells:differentiation,phenotype and role in inflammatory disease[J].Immunol Lett,2016.[Epub ahead of print]

[12]LI YK,CHEN SM.The effectiveness of adefovir dipivoxil plus Interferon on serum IL-17 in patients with chronic hepatitis B[J].China Prac Med,2013,8(22):15-16.(in Chinese)李玉魁,陈疏敏.阿德福韦酯联合干扰素对慢性乙型病毒性肝炎患者血清IL-17的影响[J].中国实用医药,2013,8(22):15-16.

[13]WANG C,SU L,CHEN SJ,et al.Roles of different subtypes of CD4+T lymphocytes in IFN-αtherapy for hepatitis B[J].J Shandong Univ:Health Sciences,2013,48(3):109-112.(in Chinese)王灿,苏良,陈士俊,等.不同亚型的CD4+T淋巴细胞在干扰素抗乙肝病毒治疗中的作用[J].山东大学学报:医学版,2013,48(3):109-112.

[14]LIU L,WANG K,ZHAO YR.Detection of serum level of interleukin-17 in patients with HBeA g-Positive chronic hepatitis B treated with interferon alpha[J].Shanxi Med J,2010,39(3):331-334.(in Chinese)刘莉,王科,赵英仁.α-干扰素治疗HBeA g阳性慢性乙型肝炎血清IL-17水平的动态检测[J].陕西医学杂志,2010,39(3):331-334.

施引文献

资源附件(0)

访问统计